Targeting Neoantigens for Personalised Immunotherapy Antonia L. Pritchard Leading Article 08 March 2018 Pages: 99 - 109
Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside Leo F BuckleyAntonio Abbate Leading Article 16 March 2018 Pages: 111 - 118
Guselkumab for the Treatment of Psoriasis Álvaro MachadoTiago Torres Review Article 22 February 2018 Pages: 119 - 128
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained Matti AaproAndriy KrendyukovPere Gascón Review Article Open access 07 February 2018 Pages: 129 - 135
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained Matti AaproAndriy KrendyukovPere Gascón Correction 28 February 2018 Pages: 137 - 138
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis Edouard LedentHugo ArleguiGaëlle Nachbaur Original Research Article Open access 27 March 2018 Pages: 139 - 152
Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP® Yeong Ran JeongRae Ung JeongGyun Min Lee Original Research Article 19 March 2018 Pages: 153 - 168
Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I William M. PardridgeRuben J. BoadoMathias Schmidt Original Research Article 13 February 2018 Pages: 169 - 176
Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes Riccardo Perfetti Letter to the Editor Open access 15 March 2018 Pages: 177 - 177
Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes” Yvette N. LambYahiya Y. Syed Letter to the Editor 15 March 2018 Pages: 179 - 179
Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes Yvette N. LambYahiya Y. Syed Correction 06 March 2018 Pages: 181 - 181